- Despite decades of research, most peptide therapeutics and other macromolecule drugs require needle administration due to insufficient oral bioavailability.
- A new gastrointestinal (GI) model system, called the GI-ORIS, enables high-throughput screening of oral drug absorption for the systematic identification of formulations that enhance oral bioavailability. The system is highly predictive of oral bioavailability in vivo while allowing a sample throughput of several thousand samples per day.
- GI-ORIS screening experiments identified new oral formulations for peptide and antisense oligonucleotide therapeutics that achieve substantial oral bioavailability enhancement suggesting widespread application of this new approach.
Thomas von Erlach, Co-Founder and Chief Scientific Officer, Vivtex